对熊去氧胆酸应答不佳或不耐受的原发性胆汁性胆管炎患者应用奥贝胆酸和贝特类药物治疗的研究进展  

Research advances in obeticholic acid and fibrates in treatment of primary biliary cholangitis with poor response or intolerance to ursodeoxycholic acid

作　　者：帅俊芳 韩子岩[1] SHUAI Junfang;HAN Ziyan(Department of Gastroenterology,The Second Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第二医院消化内科,太原030001

出　　处：《临床肝胆病杂志》2022年第4期913-917,共5页Journal of Clinical Hepatology

摘　　要：熊去氧胆酸治疗原发性胆汁性胆管炎会发生应答不佳或不耐受,更换为奥贝胆酸或贝特类单药或联合治疗后,部分治疗方案也会出现应答不佳或不耐受。近年奥贝胆酸和贝特类药物临床研究逐步解决这些问题,奥贝胆酸/贝特类药物与熊去氧胆酸的联合治疗对非晚期肝硬化原发性胆汁性胆管炎患者是有效和安全的。Poor response or intolerance to ursodeoxycholic acid may occur in the treatment of primary biliary cholangitis(PBC),and after switch to obeticholic acid or fibrates alone or in combination,poor response or intolerance is also observed in some treatment regimens.Clinical studies on obeticholic acid and fibrates will gradually solve these issues,and obeticholic acid/fibrates combined with ursodeoxycholic acid is safe and effective in PBC patients without advanced liver cirrhosis.

关 键 词：原发性胆汁性胆管炎 熊脱氧胆酸 奥贝胆酸 非诺贝特 苯扎贝特 

分 类 号：R575.7[医药卫生—消化系统]